等待开盘 08-20 09:30:00 美东时间
+0.010
+0.43%
受Elfabrio推动增长,Protalix BioTherapeutics 2026年第二季度营收增长26.8%至1990万美元,同时管理层重申了其全年业绩展望。
08-14 08:35
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.12 by 58.33 percent. The company reported quarterly sales of $19.896 million which beat the analyst consensus estimate of $12.931 million by 53.86 percent. This is a 2...
08-12 18:51
Protalix BioTherapeutics (PLX) is scheduled to announce Q2 earnings results on Wednesday, August 12th, before market open. The consensus EPS estimate is -$0.01, and the consensus revenue estimate is $...
08-11 23:10
Earnings Call Insights: Protalix BioTherapeutics (PLX) Q1 2026 Management View “During the quarter, we received a $25 million milestone from Chiesi, following the European Commission approval of Elfab...
05-13 23:52
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is a 200 percent increase over losses of $(0.05) per share
05-13 19:02
Protalix BioTherapeutics press release (PLX): Q1 GAAP EPS of $0.22 Revenue of $33.75M (+233.8% Y/Y) The Company reaffirms its previously stated 2026 revenue expectations: Total revenue in 2026 to ra...
05-13 18:53
Protalix BioTherapeutics (PLX) is scheduled to announce Q1 earnings results on Wednesday, May 13th, before market open. The consensus EPS estimate is -$0.01, and the consensus revenue estimate is $11....
05-13 02:07
今日重点评级关注:RBC Capital:维持4D Molecular Therapeutics"跑赢大市"评级,目标价从32美元升至35美元;巴克莱:维持CytomX医疗"超配"评级,目标价从10美元升至16美元
03-20 15:53